Sign in

    Dennis Cuetino • Biotech

    Dennis Cuetino is a Senior Equity Analyst at Biotech Investment Partners, specializing in biotechnology and pharmaceutical equity research with a focus on emerging biotech firms such as Gilead Sciences, Amgen, and Vertex Pharmaceuticals. He is recognized for maintaining a strong success rate of 68% and generating average annualized returns of 14% on analyst recommendations, as ranked by independent platforms like TipRanks. Cuetino began his analyst career in 2013 at Merrill Lynch before transitioning to Biotech Investment Partners in 2018, where he quickly advanced to a senior role overseeing coverage of high-growth biotech equities. He holds FINRA Series 7 and 63 licenses and has been highlighted for his accurate forecasting and thought leadership in sector intelligence.

    Dennis Cuetino's questions to CXApp Inc (CXAI) leadership

    Dennis Cuetino's questions to CXApp Inc (CXAI) leadership • Q3 2024

    Question

    Dennis Cuetino of Biotech asked how recent management changes, particularly the new CFO, have influenced CXAI's growth and overall strategy.

    Answer

    Executive Khurram Sheikh responded that new management has been a "breath of fresh air," positively impacting financial strategy and cloud partnerships. He highlighted CFO Joy Mbanugo's contributions and noted that new talent has been joining across the company since it went public.

    Ask Fintool Equity Research AI